Navigation Links
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Date:3/26/2009

h continues on innovative medicines to address the unmet needs of patients.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in Ohio.

This press release contains forward-looking statements about Amylin, Lilly and Alkermes and the investigational drug, exenatide once weekly. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYETTA and/or exenatide once weekly and the revenues generated from BYETTA may be affected by competition; unexpected new data; safety and technical issues; clinical trials, including the clinical trials mentioned in this press release, not being completed in a timely manner, not confirming previous results, or not achieving the intended clinical endpoints; the DURATION-1 study extension results potentially not being accepted to support comparability; pre-clinical trials not predicting future results; label expansion requests or NDA filings, including the NDA filing mentioned in this press release, not being submitted in a timely manner; regulatory a
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
11. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 02, 2014 Myriant Corporation, a ... of a distribution agreement with Azelis Group, a ... Myriant’s bio-succinic acid in the Nordics, Benelux, France, ... customers in the industrial and base chemicals markets. ... offers a far-reaching chemical portfolio with extensive distribution ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The inventors ... cure for chronic tinnitus are seeking support for development ... the Indiegogo platform ( http://igg.me/at/tinaway ), was launched on ... a therapeutic ‘mHealth’ app and is based on ten ... a team of biomedical and software engineers, Dr. Ian ...
(Date:8/31/2014)... Available spectra is similar for ... and cultivation of a wide range of plants. ... with proven patented and pending wide spectrum technology. ... in critical applications in contrast to growth spectra ... customers have a large variety of differently sized ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... expansion of PROVENT(R) Sleep Apnea Therapy in Limited ... Inc. a privately-held, medical device company, focused on ... the appointment of John McCutcheon as President and ... company also announced that current CEO Jeffrey Nugent ...
... Group (OTC Bulletin Board: SNBP) is pleased to ... Director of Marketing.Ms. Tan joins Sinobiopharma from Organon ... China-based Unit Marketing Director for Organon, which was ... Tan held senior marketing management roles at China ...
... Kiadis,Pharma reported preliminary clinical data on ATIR(TM) ... Data was presented by the,company,s principal investigator ... Symposium at the Annual European Bone Marrow ... March 30, 2009. Only the 6,highest ranked ...
Cached Biology Technology:Ventus Medical Appoints John McCutcheon as President and CEO 2Sinobiopharma, Inc. Appoints New Director of Marketing 2Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations 2
(Date:9/2/2014)... through a U.S. suburb , Observations and mapping ... the hours and days after the August 24 earthquake ... earthquake caused so much damage in the region, according ... by the American Geophysical Union. , ... Places to Direct Our Curiosity , Selecting where ...
(Date:9/2/2014)... The Field Museum will present the prestigious Parker/Gentry Award ... commitment to biodiversity conservation awareness. The Parker/Gentry Award is ... individual, team or organization whose efforts have had a ... and whose actions can serve as a model to ... an environmental science and conservation news website that draws ...
(Date:9/2/2014)... In Bavaria, the Tithonian Konservat-Lagersttte of lithographic limestone ... discoveries of emblematic fossils from that area (for ... have found fossil insects in the French equivalent ... new species representing the oldest known water treader. ... equivalent Bavarian outcrops, fewer fossils have been obtained ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... marine animals find their way back to their birthplace to ... has mystified scientists for more than a century. But marine ... think they might finally have unraveled the secret. At ... read the magnetic field of their home area and "imprint" ...
... from the California Institute of Technology (Caltech) have created ... the first time, the connection between the configuration of ... More precisely, they showed that the muscular band--which ... a helix--is actually a sort of twisting highway along ...
... (ST. LOUIS): The Missouri Botanical Garden Press (MBG ... species of vascular plants for the Southern Cone region, ... Plantas Vasculares del Cono Sur (Catalogue of the Plants ... the plants of Argentina, southern Brazil, Chile, Paraguay and ...
Cached Biology News:No place like home: New theory for how salmon, sea turtles find their birthplace 2No place like home: New theory for how salmon, sea turtles find their birthplace 3Caltech scientists show function of helical band in heart 2Missouri Botanical Garden publishes first catalogue of plants of the Southern Cone 2
... label transfer is fast emerging as a ... and confirmation. Until now, only amino groups ... label transfer reagents such as our Sulfo-SBED. ... Mts-Atf-LC-Biotin, are exciting additions to the protein ...
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... transfer is fast emerging as a powerful ... confirmation. Until now, only amino groups have ... transfer reagents such as our Sulfo-SBED. Sulfhydryl-reactive ... are exciting additions to the protein interaction ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
Biology Products: